Nicaraven |
| Catalog No.GC10912 |
Hydroxyl radical scavenger
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 79455-30-4
Sample solution is provided at 25 µL, 10mM.
;)
_1-7.$$$37316672@70.jpg');)
;)
;)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
;)
;)
;)
_1124-1138.$$$35908550@30.jpg');)
_766-780.$$$37100057@30.jpg');)
_418-432.$$$36893736@30.jpg');)
_240-255.$$$35108512@29.jpg');)
_533-545.$$$36543525@28.jpg');)
_264-276.$$$36600053@22.jpg');)
_2214998.$$$@0.jpg');)
Nicaraven is a novel chemically synthesized hydroxyl radical-specific scavenger.
The maximum aggregation rate induced by adenosine diphosphate (ADP) is significantly inhibited by nicaraven at concentration ranges of 350 μM or higher in the healthy volunteer platelets. The maximum aggregation rate induced by collagen is significantly inhibited by 1.75 mM of nicaraven[1].
Nicaraven inhibits lipid peroxidation in the liver, improves hepatic and systemic hemodynamics and energy metabolism, and suppresses liver enzyme release, endothelin-1 elevation in hepatic venous blood, histologic damage, and neutrophil infiltration into the liver[1]. Nicaraven increases the number of c-kit(+) stem/progenitor cells in bone marrow and peripheral blood, with a recovery rate around 60-90% of age-matched non-irradiated healthy mice. The potency of colony forming from hematopoietic stem/progenitor cells as indicator of function is completely protected with nicaraven treatment[2]. Administration of nicaraven significantly increases the number, improves the colony-forming capacity, and decreases the DNA damage of hematopoietic stem/progenitor cells. The urinary levels of 8-oxo-2′-deoxyguanosine, a marker of DNA oxidation, are significantly lower in mice that are given nicaraven compared with those that receive a placebo. The administration of nicaraven significantly decreases the levels of the inflammatory cytokines IL-6 and TNF-α in the plasma of mice[3].
References:
[1]. Komiya T, et al. A novel free radical scavenger, nicaraven, inhibits human platelet aggregation in vitro. Clin Neuropharmacol. 1999 Jan-Feb;22(1):11-4.
[2]. Yokota R, et al. A novel hydroxyl radical scavenger, nicaraven, protects the liver from warm ischemia and reperfusion injury. Surgery. 2000 Jun;127(6):661-9.
[3]. Ali H, et al. The potential benefits of nicaraven to protect against radiation-induced injury in hematopoietic stem/progenitor cells with relative low dose exposures.
[4]. Nicaraven attenuates radiation-induced injury in hematopoietic stem/progenitor cells in mice. PLoS One. 2013;8(3):e60023.
|
Animal experiment: |
Mice: To investigate the protective effect and related mechanisms of nicaraven on radiation-induced injury in hematopoietic stem/progenitor cells, 12 mice are exposed to 1 Gy γ-rays daily for 5 days in succession (a total of 5 Gy) and are then given intraperitoneal injections of nicaraven (100 mg/kg/day, Nicaraven group; n=6) or saline only (Placebo group; n=6), respectively, soon after each exposure. The mice are sacrificed 2 days after the last exposure, and samples of urine, blood, and bone marrow cells are collected and used for the following experiments[3]. |
|
References: [1]. Komiya T, et al. A novel free radical scavenger, nicaraven, inhibits human platelet aggregation in vitro. Clin Neuropharmacol. 1999 Jan-Feb;22(1):11-4. |
|
| Cas No. | 79455-30-4 | SDF | |
| Chemical Name | N-[2-(pyridine-3-carbonylamino)propyl]pyridine-3-carboxamide | ||
| Canonical SMILES | CC(CNC(=O)C1=CN=CC=C1)NC(=O)C2=CN=CC=C2 | ||
| Formula | C15H16N4O2 | M.Wt | 284.31 |
| Solubility | ≥ 14.5mg/mL in DMSO | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.5173 mL | 17.5864 mL | 35.1729 mL |
| 5 mM | 0.7035 mL | 3.5173 mL | 7.0346 mL |
| 10 mM | 0.3517 mL | 1.7586 mL | 3.5173 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 8 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *